Clinical Trial Update: Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia [Phase 3]

View source ↗

Summary

Phase 3 trial of ibrutinib with rituximab in adults with Waldenström's macroglobulinemia has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Waldenström's Macroglobulinemia | Phase 3 | Status: COMPLETED | Results posted: 2020-11-16